Seattle, WA -- (SBWIRE) -- 11/07/2019 -- Acute Bacterial Skin and Skin Structure Infection (ABSSSI) is an infection of the skin and soft tissue that impacts the epidermis, dermis, and subcutaneous tissues. According to the U.S. Food and Drug Administration (FDA), ABSSSIs are lesions with cellulitis/erysipelas, wound infections, and major cutaneous abscesses occurring in a minimum surface area of 75 cm2. ABSSSI is caused due to pathogens such as Beta-hemolytic Streptococcus, Methicillin sensitive Staphylococcus aureus (MSSA), Escherichia coli, Enterococcus faecalis, Pseudomonas aeruginosa, and Methicillin resistant Staphylococcus aureus (MRSA). High incidence of drug resistant strains, especially in Staphylococcus spp. and Enterococcus spp. has led to several challenges in the treatment of ABSSSI.
High prevalence of ABSSSI and increasing R&D in the treatment of the infection is expected to boost growth of the global acute bacterial skin and skin structure infections market. For instance, in 2017, Cempra announced promising data from the phase 3 trial of Fusidic acid for the treatment of ABSSSI. In same year, Melinta Therapeutics received the U.S. FDA approval for its product Baxdela, a delafloxacin based ABSSSI medicine, available in both intravenous and oral formulations.
Request Sample Copy of Industry Experts: https://www.coherentmarketinsights.com/insight/request-sample/1531
Moreover, in 2018, Fresenius Kabi received the U.S. FDA approval for new drug application of daptomycin, a lipopeptide class of antibacterial drug, in injectable form for complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria such as Staphylococcus aureus, Streptococcus pyogenes, and Streptococcus agalactlae.
Increasing prevalence of skin and skin structure infections is also expected to boost growth of the global acute bacterial skin and skin structure infections market. For instance, according to article published in 2015 of PLoS One journal, skin and skin structure infections related hospital admissions were 1.6% in 2005, increased to 2.0% in 2011. Moreover, according to Decision Resource Group, in 2014, 11% of 2.7 million hospital admissions for ABSSSI were pediatric patients. Key players in the market are focused on developing therapies for the treatment of ABSSSI in children. For instance, in 2016, Allergan plc. received the U.S. FDA approval for its supplemental New Drug Application (sNDA) for Teflaro, for the treatment of ABSSSI in pediatric patients.
On the basis of region, the global acute bacterial skin and skin structure infections market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. The market in North America is expected to account for the largest market share over the forecast period. This is attributed to increasing focus of key players in the market on R&D of new therapies for the treatment of ABSSSI.
The PDF for the study can be requested using the following link: https://www.coherentmarketinsights.com/insight/request-pdf/1531
The market in Asia Pacific is expected to witness rapid growth over the forecast period. This is attributed to increasing collaboration activities in the region. For instance, in 2017, Basilea Pharmaceutics Ltd. signed an agreement with Shenzhen China Resources Gosun Pharmaceutical Co. granting marketing of its product Zevtera for the treatment of Methicillin resistant Staphylococcus aureus infection in China, Hong Kong, and Macao.
Key players in the market are focused on adopting M&A strategies to expand their product portfolio. For instance, in 2014, Merck & Co., Inc. acquired Cubist Pharmaceuticals for US$ 9.5 billion. Under the acquisition, Merck acquired Cubist Pharmaceuticals' presently marketed and late stage pipeline products. Moreover, in 2017, Cempra, Inc.— a clinical-stage pharmaceutical company focused on developing treatment of infectious diseases merged with Melinta Therapeutics, a privately held company focused on discovering, developing, and commercializing novel antibiotics to treat serious bacterial infections. The merger commercialized the launch of Melinta's Baxdela, a fluoroquinolone based ABSSSI treatment for susceptible bacteria.
Major players operating in the global acute bacterial skin and skin structure infections (ABSSSI) market include, Fresenius SE & Co. KGaA, Sandoz Inc. (a subsidiary of Novartis), Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Allergan plc, Merck & Co., Inc., Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Ltd.), Glenmark Pharmaceuticals Ltd, Cadila Healthcare Ltd., and Teva Pharmaceutical Industries Ltd.
Inquire about Discount on this Report: https://www.coherentmarketinsights.com/insight/request-discount/1531
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Name: Mr. Raj Shah
Phone: US +12067016702 / UK +4402081334027
Email: ales@coherentmarketinsights.com